JNJ-26990990
Experimental anticonvulsant drug
From Wikipedia, the free encyclopedia
JNJ-26990990 is a broad-spectrum anticonvulsant drug currently under development by Janssen Pharmaceutica as a second-generation follow-up to the marketed drug topiramate.[1][2] It was designed to have the same anticonvulsant effects as topiramate, but without the side effects associated with topiramate's carbonic anhydrase inhibition.[1] It also has potential use in the treatment of inflammatory pain, neuropathic pain, and depression.[3]
Other namesN-((Benzo[b]thien-3-yl)methyl)sulfamide
| |
| Clinical data | |
|---|---|
| Other names | N-((Benzo[b]thien-3-yl)methyl)sulfamide |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C9H10N2O2S2 |
| Molar mass | 242.31 g·mol−1 |
  (what is this?) (verify) | |
JNJ-26990990 entered phase II clinical trials in October 2007.[4]
Metabolites and radioactive isotope-labeled derivatives of JNJ-26990990 have also been prepared to support its development.[5]